The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Can ruxolitinib replace hydroxyurea as a frontline therapy for polycythemia vera?
Featured:
Claire HarrisonDuring the International Academy for Clinical Hematology (IACH) 2023 Congress, the MPN Hub spoke with Claire Harrison, Guy's and St Thomas' NHS Foundation Trust, London, UK. We asked, Can ruxolitinib replace hydroxyurea as a frontline therapy for polycythemia vera?
Harrison begins by reflecting on current frontline treatment options for patients with polycythemia vera and mentions the introduction of ruxolitinib as a second-line treatment choice. She then discusses whether treatment with a drug is always an appropriate frontline option, outlining clinical scenarios when this should be strongly considered. Harrison continues by evaluating the choice of ruxolitinib or hydroxyurea, specifically in high-risk patients. Finally, she highlights important points from the recent phase II MAJIC-PV study (ISRCTN61925716).
Can ruxolitinib replace hydroxyurea as a frontline therapy for PV?
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
